An anti‑MuSK test is a blood immunoassay that detects antibodies against muscle‑specific kinase (MuSK), a protein at the neuromuscular junction. It helps diagnose a subtype of myasthenia gravis when acetylcholine receptor antibodies are negative, confirming an autoimmune cause and guiding treatment decisions. A positive result indicates MuSK‑antibody–mediated myasthenia gravis and can affect therapy choice.

A normal anti‑MuSK antibody result is essentially negative or below the laboratory’s reference cutoff. Many labs report undetectable levels or values under the assay’s threshold (commonly <0.4 U/mL, though cutoffs vary). Results must be interpreted against the lab-specific reference range and clinical context, so discuss any abnormal or borderline result with your clinician.

An anti-smooth muscle antibody (ASMA) test detects antibodies that target smooth muscle proteins. It is used primarily to help diagnose autoimmune hepatitis and to investigate unexplained abnormal liver tests or symptoms of chronic liver disease. A positive ASMA supports but does not confirm autoimmune hepatitis—results are interpreted with clinical findings, other autoimmune markers (eg ANA, LKM), IgG levels, and sometimes liver biopsy.

Anti‑MuSK antibodies in pregnant women with MuSK‑positive myasthenia gravis can worsen maternal muscle weakness—especially bulbar and respiratory symptoms—and cross the placenta, causing transient neonatal myasthenia (poor feeding, hypotonia, respiratory compromise). Pregnancy needs close neurology–obstetric monitoring, possible medication adjustments, and preparedness for neonatal support; immunotherapy (IVIG or plasmapheresis) may be used for severe maternal or neonatal disease.

MuSK-antibody–positive myasthenia gravis is treated primarily with immunotherapy: high-dose corticosteroids and steroid-sparing agents (azathioprine, mycophenolate). Rituximab is particularly effective in MuSK-positive cases. Acute exacerbations are managed with plasma exchange or IVIG. Pyridostigmine is often less helpful and thymectomy generally offers little benefit. Regular monitoring for infections and steroid side effects is needed.

A positive autoimmune test indicates detection of immune markers—commonly autoantibodies (e.g., ANA, rheumatoid factor, anti‑CCP) or elevated inflammatory markers—suggesting the immune system is reacting against the body's own tissues. It supports, but does not alone confirm, an autoimmune diagnosis; results must be interpreted with symptoms, exam, and sometimes imaging or biopsy. False positives and variable titres mean follow‑up testing and specialist evaluation are often required.